Market Overview

Teva to Present Positive Data for Glatiramer Acetate 40 mg/1 ml Given Three Times Weekly for Relapsing-Remitting Multiple Sclerosis

Teva Pharmaceutical (NYSE: TEVA) today announced data
from the Phase III Glatiramer Acetate Low-Frequency Administration
(GALA) study. The GALA study was designed to evaluate the efficacy,
safety and tolerability of an investigational dosing regimen of
glatiramer acetate (GA), the therapeutic agent in COPAXONE®
(glatiramer acetate injection), which is indicated for the treatment of
relapsing-remitting multiple sclerosis (RRMS). Detailed study results
will be presented at the 28th Congress of the European
Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in
Lyon, France during the late-breaking news parallel session on October
13, 2012.

“We are excited about the potential to offer RRMS patients another safe
and effective treatment option

See full press release

Posted-In: News Guidance Contracts Asset Sales Management Stock Split Global

 

Related Articles (TEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters